| Literature DB >> 27302097 |
Angela E Lin1, Caroline Michot2, Valerie Cormier-Daire2, Thomas J L'Ecuyer3, G Paul Matherne3, Barrett H Barnes4, Jennifer B Humberson5, Andrew C Edmondson6, Elaine Zackai6, Matthew J O'Connor7, Julie D Kaplan8, Makram R Ebeid9, Joel Krier10, Elizabeth Krieg10, Brian Ghoshhajra11,12, Mark E Lindsay11,13,14,15.
Abstract
Myhre syndrome is a rare, distinctive syndrome due to specific gain-of-function mutations in SMAD4. The characteristic phenotype includes short stature, dysmorphic facial features, hearing loss, laryngotracheal anomalies, arthropathy, radiographic defects, intellectual disability, and a more recently appreciated spectrum of cardiovascular defects with a striking fibroproliferative response to surgical intervention. We report four newly described patients with typical features of Myhre syndrome who had (i) a mildly narrow descending aorta and restrictive cardiomyopathy; (ii) recurrent pericardial and pleural effusions; (iii) a large persistent ductus arteriosus with juxtaductal aortic coarctation; and (iv) restrictive pericardial disease requiring pericardiectomy. Additional information is provided about a fifth previously reported patient with fatal pericardial disease. A literature review of the cardiovascular features of Myhre syndrome was performed on 54 total patients, all with a SMAD4 mutation. Seventy percent had a cardiovascular abnormality including congenital heart defects (63%), pericardial disease (17%), restrictive cardiomyopathy (9%), and systemic hypertension (15%). Pericarditis and restrictive cardiomyopathy are associated with high mortality (three patients each among 10 deaths); one patient with restrictive cardiomyopathy also had epicarditis. Cardiomyopathy and pericardial abnormalities distinguish Myhre syndrome from other disorders caused by mutations in the TGF-β signaling cascade (Marfan, Loeys-Dietz, or Shprintzen-Goldberg syndromes). We hypothesize that the expanded spectrum of cardiovascular abnormalities relates to the ability of the SMAD4 protein to integrate diverse signaling pathways, including canonical TGF-β, BMP, and Activin signaling. The co-occurrence of congenital and acquired phenotypes demonstrates that the gene product of SMAD4 is required for both developmental and postnatal cardiovascular homeostasis.Entities:
Keywords: SMAD4 mutations; TGF-β signaling; cardiovascular malformation; coarctation; congenital heart defect; pericardial effusion; pericarditis; restrictive cardiomyopathy
Mesh:
Substances:
Year: 2016 PMID: 27302097 DOI: 10.1002/ajmg.a.37739
Source DB: PubMed Journal: Am J Med Genet A ISSN: 1552-4825 Impact factor: 2.802